CD34

CD34 Informations sur la molécule

Nom anglaisHematopoietic progenitor cell antigen CD34Nombre de médicaments commercialisés1
Nombre de médicaments cliniques12Alias de la cibleCD34,CD34 Molecule,CD34 Antigen,Hematopoietic Progenitor Cell Antigen CD34,Antigens, CD34
Phase de R&D la plus avancéeApproved
Nom anglaisHematopoietic progenitor cell antigen CD34
Alias de la cibleCD34,CD34 Molecule,CD34 Antigen,Hematopoietic Progenitor Cell Antigen CD34,Antigens, CD34
Nombre de médicaments commercialisés1
Nombre de médicaments cliniques12
Phase de R&D la plus avancéeApproved

CD34 Liste de produits

  • Attribut

    Protein (3)Antibody (1)Cell Grade Beads (1)

  • Bibliothèque de produits

    En ligne (4)En recherche (1)

  • Espèces

    Human (4)Mouse (1)

  • Étiquette

    His Tag (2)His Tag & Avi Tag (1)- (2)

  • Marqueur

    Unconjugated (1)Biotin-labeled (1)PE Labeled (2)- (1)

CD34Contexte de la molécule

CD34 molecule is a cluster of differentiation molecule present on certain cells within the human body. It is a cell surface glycoprotein and functions as a cell-cell adhesion factor. It may also mediate the attachment of stem cells to bone marrow extracellular matrix or directly to stromal cells. As a ~ 110 kDa monomeric cell surface antigen, CD34 is highly glycosylated with nine potential N-linked and numerous potential O-linked glycosylation sites in its extracellular domain. The CD34 protein is a member of a family of single-pass transmembrane sialomucin proteins that show expression on early hematopoietic and vascular-associated tissue. CD34 is also an important adhesion molecule and is required for T cells to enter lymph nodes. It is expressed on lymph node endothelia whereas the L-selectin to which it binds is on the T cell. It was indicated that CD34 is a phosphorylation target for activated PKC, and couples to the hematopoietic adapter protein CrkL, which were involved in CD34 signaling pathways. CD34 is abberantly expressed in many kinds of tumors and is implicated in leukemogenesis.

CD34Alias de la molécule

CD34,RP11-328D5.2

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
CLBS-12CLBS-12Phase 2 ClinicalCaladrius Biosciences IncAtherosclerosis; Ischemia; Thromboangiitis Obliterans
Details
Retroviral ADA-transduced CD34+ cells (NHGRI/UCLA)Phase 2 ClinicalUcla Biomedical LibraryAdenosine deaminase deficiency
Details
CD34+ bone marrow stem cells (University of California)Phase 2 ClinicalThe University Of California DavisDiabetic Retinopathy; Macular Degeneration; Retinal Vein Occlusion; Retinitis Pigmentosa
Details
Autologous peripheral blood stem cell therapy (CellProthera)Phase 2 ClinicalCellprotheraMyocardial Infarction
Details
CD34 stem cell therapy (LA Childrens Hospital)Phase 2 ClinicalChildren'S Hospital Of Los AngelesHeart Failure; HIV Infections
Details
Stem cell therapeutics (ExCellThera)ECT-002; ECT-003; ECT-005; UM171 + UM092; UM171 + UM390Phase 2 ClinicalExcellthera IncLeukemia, Myeloid, Acute
Details
Lentiviral vector transduced CD34+ cells TherapyPhase 2 ClinicalGreat Ormond Street Hospital For Children Nhs Foundation TrustGranulomatous Disease, Chronic
Details
Cord blood stem cells(Tatcitus Therapeutics/Mount Sinai Health System)HSC-100Phase 1 ClinicalIcahn School Of Medicine At Mount Sinai, Tatcitus TherapeuticsHematologic Neoplasms; Hodgkin Disease; Leukemia; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma
Details
shRNA-Modified CD34 Cell TherapyKL-AI20Phase 1 ClinicalKanglin Biotech (Hangzhou) Co LtdHIV Infections
Details
Alpha-galactosidase A stem cell therapy (University Health Network/Ozmosis)Phase 1 ClinicalUniversity Health Network (Uhn)Fabry Disease
Details
Autologous CD34+ Cells Therapy (Zhongji Zhiyao (Nanjing) Biotechnology Co Ltd)GMCN-508APhase 1 ClinicalZhongji Zhiyao (Nanjing) Biotechnology Co Ltdalpha-Thalassemia
Details
Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion(German Cancer Research Center)Phase 1 ClinicalGerman Cancer Research Center (Dkfz)Leukemia, Myeloid, Acute
Details

Informations sur les médicaments commercialisés

Nom anglaisCode de recherchePhase de R&DEntreprisePlus ancien nom de marquePays d'approbation le plus ancienIndication la plus ancienneSociété d'approbation la plus ancienneDate d'approbation la plus ancienneIndicationEssai clinique
Anti-CD34 mab-sirolimus (OrbusNeich)ApprovedOrbusneichCoronary RestenosisOrbusneich2013-01-01Coronary Artery Disease; Coronary Restenosis
Details
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments commercialisés
  • Informations sur les médicaments cliniques